An open-label study of oral enzastaurin HCl in patients with advanced or metastatic malignancies
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2017
At a glance
- Drugs Enzastaurin (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Eli Lilly
- 11 Aug 2009 Actual end date (Jul 2009) and actual number of patients (23) added as reported by ClinicalTrials.gov.
- 11 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Apr 2006 New trial record.